Tango Therapeutics, Inc. TNGX
$20.87
-9.97%
at last close
Market Cap$3.91 billion
P/E Ratio—
Div Yield—
Volume3.41M
52-Week Range
$6.69$34.39
Analyst Ratings
- Consensus
- Buy — 11 Buy · 2 Hold · 0 Sell (13 analysts)
- Avg. Price Target
- $43.82 (+110.0% upside)
Key Stats
- Today's Range
- $20.78 – $23.57
- 50-Day Range
- $20.78 – $27.98
- 52-Week Range
- $6.69 – $34.39
- Volume
- 3.41 million shs
- Average Volume
- 4.18 million shs
- Market Cap
- $3.91 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.03%
- Days to Cover
- 1.00
About Tango Therapeutics, Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Related Stocks
Compare head-to-head: TNGX vs LLY·TNGX vs JNJ·TNGX vs ABBV·TNGX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.